Colombia gastric cancer drugs market is projected to register a substantial CAGR of 8.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.
Market Segmentation:
Colombia Gastric Cancer Drugs Market, By Type (Adenocarcinoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Lymphoma, and Others), Stage (Stage III, Stage II, Stage IV, Stage I, and Others), Treatment (Chemotherapy, Targeted Therapy, Immune Checkpoint Inhibitors, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Research & Academic Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Colombia gastric cancer drugs market are:
Rising Prevalence of gastric cancer
Increasing technological advancements
Market Players:
The key market players for Colombia gastric cancer drugs market are listed below:
Bayer AG
Novartis AG
Pfizer Inc.
Celltrion Healthcare Co., Ltd.
F. Hoffmann-La Roche Ltd
Merck KGaA
Teva Pharmaceutical Industries Ltd.
Sanofi
AstraZeneca
Viatris Inc.
Bristol-Myers Squibb Company
Concord Biotech
GlaxoSmithKline plc.
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 OVERVIEW OF COLOMBIA GASTRIC CANCER DRUGS MARKET 12
1.4 LIMITATIONS 13
1.5 MARKETS COVERED 14
2 MARKET SEGMENTATION 16
2.1 MARKETS COVERED 16
2.2 GEOGRAPHICAL SCOPE 17
2.3 YEARS CONSIDERED FOR THE STUDY 17
2.4 CURRENCY AND PRICING 17
2.5 DBMR TRIPOD DATA VALIDATION MODEL 18
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 21
2.7 MULTIVARIATE MODELLING 22
2.8 TYPE LIFELINE CURVE 22
2.9 DBMR MARKET POSITION GRID 23
2.10 VENDOR SHARE ANALYSIS 24
2.11 MARKET END USER COVERAGE GRID 25
2.12 SECONDARY SOURCES 26
2.13 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 30
4.1 PESTEL ANALYSIS 31
4.2 PORTERS FIVE FORCES 32
5 COLOMBIA GASTRIC CANCER DRUGS MARKET: REGULATORY SCENARIO 33
6 SUMMARY WRITE UP (COLOMBIA) 35
6.1 OVERVIEW 35
7 PIPELINE ANALYSIS FOR COLOMBIA GASTRIC CANCER DRUGS MARKET 36
8 MARKET OVERVIEW 38
8.1 DRIVERS 40
8.1.1 GROWING GASTRIC CANCER BURDEN WORLDWIDE 40
8.1.2 GROWING GERIATRIC POPULATION 40
8.1.3 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANISATIONS 41
8.1.4 RISING NUMBER OF PRODUCT APPROVALS 41
8.2 RESTRAINTS 42
8.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH GASTRIC CANCER TREATMENT DRUGS 42
8.2.2 LACK OF EARLY DETECTION OF GASTRIC CANCER 42
8.3 OPPORTUNITIES 42
8.3.1 RECENT ADVANCEMENTS IN GASTRIC CANCER TREATMENT 42
8.3.2 ADOPTION OF AUTOMATED SYSTEMS 43
8.3.3 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS 43
8.4 CHALLENGES 44
8.4.1 CHALLENGE RELATED TO COLOMBIAN HEALTHCARE 44
8.4.2 ALTERNATIVE GASTRIC CANCER THERAPIES 45
9 IMPACT OF COVID-19 PANDEMIC ON COLOMBIA GASTRIC CANCER DRUGS MARKET 46
9.1 PRICE IMPACT 46
9.2 IMPACT ON DEMAND 46
9.3 IMPACT ON SUPPLY CHAIN 47
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS 47
9.5 CONCLUSION 48
10 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TYPE 49
10.1 OVERVIEW 50
10.2 ADENOCARCINOMA 53
10.3 GASTROINTESTINAL STROMAL TUMOR 53
10.4 CARCINOID TUMOR 54
10.5 LYMPHOMA 54
10.6 OTHERS 54
11 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY STAGES 55
11.1 OVERVIEW 56
11.2 STAGE III 59
11.3 STAGE II 59
11.4 STAGE IV 59
11.5 STAGE I 60
11.6 OTHERS 60
12 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TREATMENT 61
12.1 OVERVIEW 62
12.2 CHEMOTHERAPY 65
12.2.1 CISPLATIN 66
12.2.2 OXALIPLATIN 66
12.2.3 FLUOROURACIL 66
12.2.4 DOCETAXEL 66
12.2.5 CAPECITABINE 66
12.2.6 CARBOPLATIN 66
12.2.7 EPIRUBICIN 66
12.2.8 PACLITAXEL 66
12.2.9 IRINOTECAN 66
12.2.10 OTHERS 66
12.3 TARGETED THERAPY 66
12.3.1 MONOCLONAL ANTIBODY THERAPY 67
12.3.1.1 TRASTUZUMAB (HERCEPTIN) 67
12.3.1.2 RAMUCIRUMAB 68
12.3.2 MULTIKINASE INHIBITORS 68
12.3.2.1 SUNITINIB 68
12.3.2.2 REGORAFENIB 68
12.4 IMMUNE CHECKPOINT INHIBITORS 68
12.5 OTHERS 69
13 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION 70
13.1 OVERVIEW 71
13.2 PARENTERAL 74
13.2.1 INTRAVENOUS 74
13.2.2 SUBCUTANEOUS 74
13.2.3 OTHERS 74
13.3 ORAL 74
13.3.1 TABLET 75
13.3.2 CAPSULE 75
13.3.3 OTHERS 75
13.4 OTHERS 76
13.5 OVERVIEW 78
13.6 HOSPITALS 81
13.7 SPECIALITY CLINICS 81
13.8 RESEARCH & ACADEMIC INSTITUTES 82
13.9 OTHERS 82
14 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL 83
14.1 OVERVIEW 84
14.2 HOSPITAL PHARMACY 87
14.3 RETAIL PHARMACY 87
14.4 OTHERS 87
15 COLOMBIA GASTRIC CANCER DRUGS MARKET: COMPANY LANDSCAPE 88
15.1 COMPANY SHARE ANALYSIS: GLOBAL 88
16 SWOT ANALYSIS 89
17 COMPANY PROFILE 90
17.1 F.HOFFMAN-LA ROCHE 90
17.1.1 COMPANY SNAPSHOT 90
17.1.2 REVENUE ANALYSIS 90
17.1.3 PRODUCT PORTFOLIO 91
17.1.4 RECENT DEVELOPMENT 91
17.1.4.1 AGREEMENT 91
17.2 MERCK KGAA (A SUBSIDIARY OF MERCK & CO., INC.) 92
17.2.1 COMPANY SNAPSHOT 92
17.2.2 REVENUE ANALYSIS 92
17.2.3 PRODUCT PORTFOLIO 93
17.2.4 RECENT DEVELOPMENTS 93
17.2.4.1 PRODUCT APPROVAL 93
17.2.4.2 EVENTS 93
17.3 TEVA PHARMACEUTICAL INDUSTRIES LTD 94
17.3.1 COMPANY SNAPSHOT 94
17.3.2 REVENUE ANALYSIS 94
17.3.3 PRODUCT PORTFOLIO 95
17.3.4 RECENT DEVELOPMENT 95
17.3.4.1 COLLABORATION 95
17.4 SANOFI 96
17.4.1 COMPANY SNAPSHOT 96
17.4.2 REVENUE ANALYSIS 96
17.4.3 PRODUCT PORTFOLIO 97
17.4.4 RECENT DEVELOPMENT 97
17.4.4.1 ACQUISITION 97
17.5 ASTRAZENECA 98
17.5.1 COMPANY SNAPSHOT 98
17.5.2 REVENUE ANALYSIS 98
17.5.3 PRODUCT PORTFOLIO 99
17.5.4 RECENT DEVELOPMENT 99
17.5.4.1 PRODUCT APPROVAL 99
17.6 BAYER AG 100
17.6.1 COMPANY SNAPSHOT 100
17.6.2 REVENUE ANALYSIS 100
17.6.3 PRODUCT PORTFOLIO 101
17.6.4 RECENT DEVELOPMENT 101
17.6.4.1 COLLABORATION 101
17.7 BRISTOL-MYERS SQUIBB COMPANY 102
17.7.1 COMPANY SNAPSHOT 102
17.7.2 REVENUE ANALYSIS 102
17.7.3 PRODUCT PORTFOLIO 103
17.7.4 RECENT DEVELOPMENT 103
17.7.4.1 PRODUCT APPROVAL 103
17.8 CELLTRION HEALTHCARE CO., LTD. 104
17.8.1 COMPANY SNAPSHOT 104
17.8.2 REVENUE ANALYSIS 104
17.8.3 PRODUCT PORTFOLIO 105
17.8.4 RECENT DEVELOPMENT 105
17.8.4.1 PRODUCT APPROVAL 105
17.9 CONCORD BIOTECH. 106
17.9.1 COMPANY SNAPSHOT 106
17.9.2 PRODUCT PORTFOLIO 106
17.9.3 RECENT DEVELOPMENT 106
17.10 GLAXOSMITHKLINE PLC. 107
17.10.1 COMPANY SNAPSHOT 107
17.10.2 REVENUE ANALYSIS 107
17.10.3 PRODUCT PORTFOLIO 108
17.10.4 RECENT DEVELOPMENT 108
17.10.4.1 PRODUCT APPROVAL 108
17.11 NOVARTIS AG 109
17.11.1 COMPANY SNAPSHOT 109
17.11.2 REVENUE ANALYSIS 109
17.11.3 PRODUCT PORTFOLIO 110
17.11.4 RECENT DEVELOPMENT 110
17.11.4.1 PRODUCT LAUNCH 110
17.12 PFIZER INC. 111
17.12.1 COMPANY SNAPSHOT 111
17.12.2 REVENUE ANALYSIS 111
17.12.3 PRODUCT PORTFOLIO 112
17.12.4 RECENT DEVELOPMENTS 112
17.12.4.1 MERGER 112
17.12.4.2 COLLABORATION 112
17.13 VIATRIS INC. 113
17.13.1 COMPANY SNAPSHOT 113
17.13.2 REVENUE ANALYSIS 113
17.13.3 PRODUCT PORTFOLIO 114
17.13.4 RECENT DEVELOPMENT 114
18 QUESTIONNAIRE 115
19 RELATED REPORTS 118
Segmentation
Short Description
Colombia Gastric Cancer Drugs Market, By Type (Adenocarcinoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Lymphoma, and Others), Stage (Stage III, Stage II, Stage IV, Stage I, and Others), Treatment (Chemotherapy, Targeted Therapy, Immune Checkpoint Inhibitors, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Research & Academic Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others). Industry Trends and Forecast to 2029
Market Definition:
Gastric cancer is a disease in which malignant (cancer) cells form in the lining of the stomach.
Age, diet, and stomach disease can affect the risk of developing gastric cancer.
Symptoms of gastric cancer include indigestion and stomach discomfort or pain.
Tests that examine the stomach and esophagus are used to diagnose gastric cancer.
Certain factors affect prognosis (chance of recovery) and treatment options.
The wall of the stomach is made up of five layers of tissue. From the innermost layer to the outermost layer, the layers of the stomach wall are: mucosa, submucosa, muscle, subserosa (connective tissue), and serosa. Gastric cancer begins in the mucosa and spreads through the outer layers as it grows.
Market Segmentation:
Colombia gastric cancer drugs market is categorized into six notable segments which are based on type, stage, treatment, route of administration, end user and distribution channel.
On the basis of type, the market is segmented into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor and others
On the basis of stage, the market is segmented into stage I, stage II, stage III, stage IV, and others
On the basis of treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy and others
On the basis of route of administration, the market is segmented into oral and parenteral and others
On the basis of end user, the market is segmented into speciality clinics, hospitals, research and academic institutes and others
On the basis of distribution channel, the market is segmented into retail pharmacy, hospital pharmacy and others
Market Players
The key market players for Colombia gastric cancer drugs market are listed below:
Bayer AG
Novartis AG
Pfizer Inc.
Celltrion Healthcare Co., Ltd.
F. Hoffmann-La Roche Ltd
Merck KGaA
Teva Pharmaceutical Industries Ltd.
Sanofi
AstraZeneca
Viatris Inc.
Bristol-Myers Squibb Company
Concord Biotech
GlaxoSmithKline plc.
Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
